Literature DB >> 23896686

A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans.

Jennifer L A Rabjohns1, Yoon-Dong Park1, Jean Dehdashti2, Christina Henderson3, Adrian Zelazny3, Steven J Metallo4, Wei Zheng2, Peter R Williamson1,5.   

Abstract

Cryptococcus neoformans is a pathogenic fungus that causes meningitis worldwide, particularly in human immunodeficiency virus (HIV)-infected individuals. Although amphotericin B is the "gold standard" treatment for cryptococcal meningitis, the toxicity and inconvenience of intravenous injection emphasize a need for development of new anticryptocccal drugs. Recent data from humans and animal studies suggested that a nutrient-deprived host environment may exist in cryptococcal meningitis. Thus, a screening assay for identifying fungicidal compounds under nutrient-deprived conditions may provide an alternative strategy to develop new anticryptococcal drugs for this disease. A high-throughput fungicidal assay was developed using a profluorescent dye, alamarBlue, to detect residual metabolic activity of C. neoformans under nutrient-limiting conditions. Screening the Library of Pharmacologically Active Compounds (LOPAC) with this assay identified a potential chemical scaffold, 10058-F4, that exhibited fungicidal activity in the low micromolar range. These results thus demonstrate the feasibility of this alamarBlue-based assay for high-throughput screening of fungicidal compounds under nutrient-limiting conditions for new anticryptococcal drug development.

Entities:  

Keywords:  Cryptococcus neoformans; alamarBlue assay; fungicidal screen; high-throughput screen

Mesh:

Substances:

Year:  2013        PMID: 23896686      PMCID: PMC4017337          DOI: 10.1177/1087057113496847

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  30 in total

1.  c-Myc inhibition negatively impacts lymphoma growth.

Authors:  Ilsa Gomez-Curet; R Serene Perkins; Ryan Bennett; Katherine L Feidler; Stephen P Dunn; Leslie J Krueger
Journal:  J Pediatr Surg       Date:  2006-01       Impact factor: 2.545

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Cryptococcus neoformans gene expression during murine macrophage infection.

Authors:  Weihua Fan; Peter R Kraus; Marie-Josee Boily; Joseph Heitman
Journal:  Eukaryot Cell       Date:  2005-08

4.  Prognostic factors in cryptococcal meningitis. A study in 111 cases.

Authors:  R D Diamond; J E Bennett
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

5.  Cryptococcomas distinguished from gliomas with MR spectroscopy: an experimental rat and cell culture study.

Authors:  U Himmelreich; T E Dzendrowskyj; C Allen; S Dowd; R Malik; B P Shehan; P Russell; C E Mountford; T C Sorrell
Journal:  Radiology       Date:  2001-07       Impact factor: 11.105

6.  Ferrous iron uptake in Cryptococcus neoformans.

Authors:  E S Jacobson; A P Goodner; K J Nyhus
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Comparison of alamar blue and MTT assays for high through-put screening.

Authors:  R Hamid; Y Rotshteyn; L Rabadi; R Parikh; P Bullock
Journal:  Toxicol In Vitro       Date:  2004-10       Impact factor: 3.500

8.  Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase.

Authors:  P R Williamson
Journal:  J Bacteriol       Date:  1994-02       Impact factor: 3.490

9.  Effects of melanin upon susceptibility of Cryptococcus to antifungals.

Authors:  Reiko Ikeda; Takashi Sugita; Eric S Jacobson; Takako Shinoda
Journal:  Microbiol Immunol       Date:  2003       Impact factor: 1.955

10.  Epidemiology of cryptococcal meningitis in the US: 1997-2009.

Authors:  Vasilios Pyrgos; Amy E Seitz; Claudia A Steiner; D Rebecca Prevots; Peter R Williamson
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more
  13 in total

Review 1.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 2.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

Review 3.  Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility.

Authors:  Nina T Grossman; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

4.  Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen.

Authors:  Yu-Shan Cheng; Jose Santinni Roma; Min Shen; Caroline Mota Fernandes; Patricia S Tsang; He Eun Forbes; Helena Boshoff; Cristina Lazzarini; Maurizio Del Poeta; Wei Zheng; Peter R Williamson
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions.

Authors:  Seameen J Dehdashti; Jennifer Abbott; Dac-Trung Nguyen; John C McKew; Peter R Williamson; Wei Zheng
Journal:  Anal Bioanal Chem       Date:  2013-06-30       Impact factor: 4.142

6.  Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Maureen J Donlin; Thomas R Lane; Olga Riabova; Alexander Lepioshkin; Evan Xu; Jeffrey Lin; Vadim Makarov; Sean Ekins
Journal:  ACS Med Chem Lett       Date:  2021-04-07       Impact factor: 4.345

7.  Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens.

Authors:  Wei Sun; Yoon-Dong Park; Janyce A Sugui; Annette Fothergill; Noel Southall; Paul Shinn; John C McKew; Kyung J Kwon-Chung; Wei Zheng; Peter R Williamson
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

8.  Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening.

Authors:  Yoon-Dong Park; Wei Sun; Antonio Salas; Avan Antia; Cindy Carvajal; Amy Wang; Xin Xu; Zhaojin Meng; Ming Zhou; Gregory J Tawa; Jean Dehdashti; Wei Zheng; Christina M Henderson; Adrian M Zelazny; Peter R Williamson
Journal:  MBio       Date:  2016-08-02       Impact factor: 7.867

9.  High-Throughput Screen in Cryptococcus neoformans Identifies a Novel Molecular Scaffold That Inhibits Cell Wall Integrity Pathway Signaling.

Authors:  Kate Hartland; Jun Pu; Michelle Palmer; Sivaraman Dandapani; Philip N Moquist; Benito Munoz; Louis DiDone; Stuart L Schreiber; Damian J Krysan
Journal:  ACS Infect Dis       Date:  2015-11-06       Impact factor: 5.084

Review 10.  New Horizons in Antifungal Therapy.

Authors:  Kaila M Pianalto; J Andrew Alspaugh
Journal:  J Fungi (Basel)       Date:  2016-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.